NEW YORK, March 25 (GenomeWeb News) - Lynx Therapeutics and Solexa have acquired technology for generating DNA colonies from Manteia, the companies said today.
The technology, from Swiss-based Manteia, generates millions of DNA fragments from a single DNA molecule to create DNA colonies, or clusters on a surface.
Lynx, based in Hayward, Calif., plans to replace its Megaclone micro-beads, part of its Massively Parallel Signature Sequencing technology, with the DNA cluster approach. As a result, the company will be able to deliver its technology and instrumentation directly to customers, according to Lynx CEO Kevin Corcoran.
Solexa, of Essex, UK, plans to integrate the DNA cluster technology into its sequencing system, based on single molecule arrays. This will enable the company to launch a product earlier, according to Solexa's CEO, Nick McCooke.
Lynx and Solexa also said they anticipate further collaborations based on the DNA cluster technology.